Treatment Results of Hodgkin's Disease in Indian Children

Gauri Kapoor(Tata Memorial Hospital), Purvish M. Parikh(Tata Memorial Hospital), S.K. Shrivastava(Tata Memorial Hospital), M.A. Muckaden(Homi Bhabha National Institute), C.S. Soman(Tata Memorial Hospital), R. Gopal(Bombay Hospital), Vinay Sharma(Tata Memorial Hospital), C. N. Nair(Tata Memorial Hospital), Tapan K. Saikia(Tata Memorial Hospital), K.A. Dinshaw(Tata Memorial Hospital), Suresh H. Advani(Jaslok Hospital), Suresh K. Pai(Tata Memorial Hospital), Kurkure Pa(Tata Memorial Hospital), Vidya Pai(Tata Memorial Hospital)
Pediatric Hematology and Oncology
January 1, 1995
10.3109/08880019509030770
Cited by 22

Related Papers

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
|The Lancet|2005|2.1k
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2006|705
Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need?
|Journal of Clinical Oncology|2003|202
Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study
|Journal of Thoracic Oncology|2006|168
Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study
|Journal of Thoracic Oncology|2006|129